RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @leitaomd: How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @leitaomd: How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
RT @leitaomd: How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @leitaomd: How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
RT @leitaomd: How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
How is this different from debulking endo ca without HIPEC? And a 3% periop mortality is unacceptable https://t.co/2HXzqem7dh
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
RT @AnnSurgOncol: MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases…
MARCH ISSUE: #CytoreductiveSurgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with #PeritonealMetastases from #EndometrialCancer. https://t.co/fgv1bVcOe3 https://t.co/4IFgA4pOl2
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @leitaomd: Results no better than cytoreduction alone reported in other series. Caution using HIPEC https://t.co/GRioYt4xaH
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @leitaomd: Results no better than cytoreduction alone reported in other series. Caution using HIPEC https://t.co/GRioYt4xaH
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT SocSurgOnc RT AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastases from #EndometrialCancer. https://t.co/3LMZVpJcnL
RT Society of Surgical Oncology https://t.co/YDJ2e2slAL
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
RT @AnnSurgOncol: AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastas…
Results no better than cytoreduction alone reported in other series. Caution using HIPEC https://t.co/GRioYt4xaH
AHEAD OF PRINT:Cytoreductive Surgery Plus Hyperthermic #IntraperitonealChemotherapy for Patients with Peritoneal Metastases from #EndometrialCancer. https://t.co/LeQrvIusbE